Skip to main content

Table 1 Baseline characteristics of patients in the SCarlet RoAD study

From: A phase III randomized trial of gantenerumab in prodromal Alzheimer’s disease

Variable Intention-to-treat population (n = 797)
Placebo
(n = 266)
Gantenerumab 105 mg
(n = 271)
Gantenerumab 225 mg
(n = 260)
Age, years, mean (SD) 69.5 (7.5) 70.3 (7.0) 71.3 (7.1)
Education, years, mean (SD) 89.8% 93.0% 91.9%
Weight, kg, mean (SD) 12.6 (4.3) 12.9 (4.8) 12.1 (4.5)
APOE ε4 genotype, %a 69.8 (12.9) 70.5 (13.6) 70.1 (12.5)
 0ε4 29.7% 21.0% 38.5%
 1ε4 50.4% 41.0% 61.5%
 2ε4 19.9% 38.0%
Clinical scores
 CDR-SB, mean score (SD) 2.1 (1.0) 2.2 (1.0) 2.0 (0.9)
 ADAS-Cog 13, mean score (SD) 23.5 (7.2) 23.1 (6.9) 23.0 (6.2)
 FAQ, mean score (SD) 4.9 (4.3) 4.6 (3.9) 4.8 (4.3)
 FCSRT-Total Recall, mean score (SD) 29.3 (10.8) 28.3 (10.8) 30.5 (10.4)
 MMSE, mean score (SD) 25.7 (2.1) 25.7 (2.3) 25.7 (2.2)
CSF biomarkers
 Aβ42, pg/ml, mean (SD) 487.8 (170.4) 475.3 (142.2) 511.8 (172.0)
 t-tau, pg/ml, mean (SD) 556.3 (203.8) 563.2 (239.1) 544.5 (220.5)
 p-tau, pg/ml, mean (SD) 84.0 (31.4) 86.3 (39.5) 82.5 (34.2)
 Neurogranin, pg/ml, mean (SD) 474.8 (260.7) 500.5 (270.0) 484.9 (293.9)
  1. Abbreviations: ADAS-Cog Alzheimer’s Disease Assessment Scale–Cognitive subscale, APOE Apolipoprotein E, CDR-SB Clinical Dementia Rating Sum of Boxes, CSF Cerebrospinal fluid, FAQ Functional Activities Questionnaire, FCSRT Free and Cued Selective Reminding Test, MMSE Mini Mental State Examination
  2. aBy design, there were no APOE 2ε4 patients in the gantenerumab 225 mg arm